Mori Katsuhito, Shoji Tetsuo, Nakatani Shinya, Uedono Hideki, Ochi Akinobu, Yoshida Hisako, Imanishi Yasuo, Morioka Tomoaki, Tsujimoto Yoshihiro, Kuro-O Makoto, Emoto Masanori
Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Clin Kidney J. 2024 Feb 29;17(3):sfae042. doi: 10.1093/ckj/sfae042. eCollection 2024 Mar.
Fetuin-A inhibits precipitation of calcium-phosphate crystals by forming calciprotein particles (CPP). A novel T50 test, which measures transformation time from primary to secondary CPP, is an index for calcification propensity. Both lower fetuin-A and shorter T50 levels were associated with cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). Extremely high risk for CVD death in advanced CKD patients consists of high-incidental CVD event and high mortality after CVD event. To date, it is unclear whether fetuin-A and/or T50 can equally predict each CVD outcome.
This prospective cohort study examined patients undergoing maintenance hemodialysis. The exposures were fetuin-A and T50. The outcomes of interests were new CVD events and subsequent deaths. The patients were categorized into tertiles of fetuin-A or T50 (T1 to T3).
We identified 190 new CVD events during the 5-year follow-up of the 513 patients and 59 deaths subsequent to the CVD events during 2.5-year follow-up. A lower fetuin-A but not T50 was significantly associated with new CVD events [subdistribution hazard ratio (HR) 1.73, 95% confidence interval (CI) 1.15-2.61, = .009 for T1 vs T3]. In contrast, a shorter T50 but not fetuin-A was a significant predictor of deaths after CVD events (HR 3.31, 95% CI 1.42-7.74, = .006 for T1 + T2 vs T3). A lower fetuin-A was predictive of new CVD events, whereas a shorter T50 was more preferentially associated with subsequent death.
These results indicate that fetuin-A and T50 are involved in cardiovascular risk in different manners.
胎球蛋白-A通过形成钙蛋白颗粒(CPP)抑制磷酸钙晶体的沉淀。一种新的T50检测方法,用于测量从初级CPP到次级CPP的转化时间,是钙化倾向的一个指标。较低的胎球蛋白-A水平和较短的T50水平都与慢性肾脏病(CKD)患者的心血管疾病(CVD)风险相关。晚期CKD患者发生CVD死亡的极高风险包括高发性CVD事件和CVD事件后的高死亡率。迄今为止,尚不清楚胎球蛋白-A和/或T50是否能同样预测每种CVD结局。
这项前瞻性队列研究对接受维持性血液透析的患者进行了检查。暴露因素为胎球蛋白-A和T50。感兴趣的结局是新发CVD事件和随后的死亡。患者被分为胎球蛋白-A或T50的三分位数(T1至T3)。
在对513例患者进行的5年随访中,我们确定了190例新发CVD事件,在2.5年随访期间,CVD事件后有59例死亡。较低的胎球蛋白-A水平而非T50水平与新发CVD事件显著相关[亚分布风险比(HR)为1.73,95%置信区间(CI)为1.15-2.61,T1与T3相比,P = 0.009]。相比之下,较短的T50水平而非胎球蛋白-A水平是CVD事件后死亡的显著预测因素(HR为3.31,95%CI为1.42-7.74,T1+T2与T3相比,P = 0.006)。较低的胎球蛋白-A水平可预测新发CVD事件,而较短的T50水平更优先与随后的死亡相关。
这些结果表明,胎球蛋白-A和T50以不同方式参与心血管风险。